XORTX Therapeutics Inc
$ 0.63
-1.09%
03 Dec - close price
- Market Cap 4,414,000 USD
- Current Price $ 0.63
- High / Low $ 0.64 / 0.62
- Stock P/E N/A
- Book Value 0.38
- EPS -0.40
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -0.95 %
- 52 Week High 1.79
- 52 Week Low 0.52
About
XORTX Therapeutics Inc. is a Vancouver-based biopharmaceutical firm focused on pioneering novel therapies for progressive kidney diseases and associated metabolic disorders, including hypertension and diabetic nephropathy. The company is actively advancing its proprietary drug candidates through clinical development, targeting significant unmet medical needs in an area with considerable patient demand. By harnessing state-of-the-art research and strategic collaborations, XORTX is positioned to commercialize impactful therapies that aim to enhance patient outcomes and contribute to the evolving healthcare marketplace.
Analyst Target Price
$13.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-15 | 2025-05-14 | 2025-03-25 | 2024-11-12 | 2024-08-14 | 2024-05-15 | 2023-12-31 | 2023-11-14 | 2023-08-14 | 2023-05-15 | 2023-03-31 |
| Reported EPS | -0.1337 | -0.19 | 0.04 | -0.81 | -0.2022 | 0.0586 | 1.3504 | -0.636 | -0.67 | -0.8 | -0.11 | -0.2 |
| Estimated EPS | -0.316 | None | None | -0.41 | None | -0.923 | -0.2767 | -0.815 | -0.19 | -1.36 | -0.1456 | -0.27 |
| Surprise | 0.1823 | 0 | 0 | -0.4 | 0 | 0.9816 | 1.6271 | 0.179 | -0.48 | 0.56 | 0.0356 | 0.07 |
| Surprise Percentage | 57.6899% | None% | None% | -97.561% | None% | 106.3489% | 588.0376% | 21.9632% | -252.6316% | 41.1765% | 24.4505% | 25.9259% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.08 | $0.07 | $0.08 | $0.08 | $0.08 | $0.07 | $0.07 | $0.07 | $0.05 | $0.05 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XRTX
2025-10-17 19:50:49
XORTX Therapeutics Inc. announced its acquisition of a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited, including the novel new chemical entity VB4-P5. The pre-IND program targets rare and prevalent forms of kidney disease, which currently lack specific anti-fibrotic treatments. The acquisition involves a USD $3.0 million payment in XORTX common shares to Vectus, pending regulatory approvals and closing documentation.
2025-10-17 14:46:48
XORTX Therapeutics (XRTX) shares surged over 40% following its announcement of a deal to acquire the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems. This program includes the molecule VB4-P5, aimed at combating kidney scarring, a significant issue in kidney disease affecting millions globally. The acquisition, valued at $3 million in XORTX shares, is seen as a strategic move to address a large unmet medical need, aligning with XORTX's existing focus on kidney and gout treatments.
2025-10-17 14:24:17
This article provides live stock price information for XORTX Therapeutics Inc. (XRTX), showing its current price and daily percentage change. It also indicates the absence of recent analyst ratings and earnings information for the company.
2025-10-17 14:04:00
XORTX Therapeutics Inc. (NASDAQ: XRTX) has seen a significant stock surge of 34.15% driven by promising clinical trial results for a new kidney disease treatment and strategic collaborations. While the company exhibits strong financial health with a quick ratio of 1.5 and low liabilities, analysts and investors debate the sustainability of this rapid increase, emphasizing the need to monitor future quarterly reports and market responses to its innovations. The article highlights both the exciting potential in biotech breakthroughs and the critical importance of risk management in volatile markets.
2025-10-17 13:47:44
XORTX Therapeutics stock surged 20% today following its acquisition of a promising kidney disease treatment, VB4-P5, from Vectus Biosystems Limited. This new chemical entity, currently in pre-IND stage, is aimed at treating rare and prevalent forms of kidney disease and shows potential to inhibit and reverse kidney fibrosis. The acquisition aligns with XORTX's strategy to develop innovative therapies for progressive renal disorders, leading to significant trading volume for XRTX shares.
2025-10-17 13:18:00
XORTX Therapeutics Inc. (NASDAQ: XRTX) stock is trending up by 38.81% following promising FDA designations and positive trial outcomes. Despite this surge, the company faces financial challenges, including significant operational expenses and a lack of income from continuous operations. Investors are weighing the potential for future growth from research breakthroughs against current financial metrics and market volatility in the biotech sector.
